Chemomab Therapeutics (NASDAQ:CMMB) Earns “Outperform” Rating from Oppenheimer

Oppenheimer reiterated their outperform rating on shares of Chemomab Therapeutics (NASDAQ:CMMB) in a research note released on Friday morning,Benzinga reports. The brokerage currently has a $11.00 price objective on the stock, down from their previous price objective of $13.00.

Chemomab Therapeutics Stock Down 3.7 %

NASDAQ:CMMB traded down $0.06 on Friday, reaching $1.68. The company’s stock had a trading volume of 264,452 shares, compared to its average volume of 187,071. The firm has a market cap of $24.05 million, a price-to-earnings ratio of -1.68 and a beta of 0.53. Chemomab Therapeutics has a 12-month low of $0.42 and a 12-month high of $2.55. The stock has a 50 day moving average price of $1.56 and a 200 day moving average price of $1.27.

Chemomab Therapeutics (NASDAQ:CMMB) last released its quarterly earnings results on Wednesday, August 21st. The company reported ($0.26) EPS for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.06). During the same period in the prior year, the business posted ($0.72) earnings per share. Equities research analysts expect that Chemomab Therapeutics will post -0.9 EPS for the current fiscal year.

Institutional Trading of Chemomab Therapeutics

A hedge fund recently bought a new stake in Chemomab Therapeutics stock. Sphera Funds Management LTD. bought a new position in shares of Chemomab Therapeutics Ltd. (NASDAQ:CMMB) in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 1,214,575 shares of the company’s stock, valued at approximately $1,907,000. Sphera Funds Management LTD. owned 8.46% of Chemomab Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC). 46.05% of the stock is owned by institutional investors.

Chemomab Therapeutics Company Profile

Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody had completed Phase 2a clinical trials that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc).